Abstracts tagged "gout and technology"

Abstract Number: 2244 • 2018 ACR/ARHP Annual Meeting
Comparison of an Interactive Voice Response (IVR) to Smart Phone App to Determine Patient Preference for Reporting Gout Flares
Nada Elmagboul¹, Brian W Coburn², Kenneth Saag¹, Phillip J. Foster³, Amy S. Mudano¹, Joshua A. Melnick⁴, Debra A Bergman², Shuo Yang¹, David T. Redden⁵, Lang Chen¹, Filby Cooper¹, Jeffrey R. Curtis¹ and Ted R. Mikuls⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ³Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁶Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Gout flares are a major cause of morbidity and are an important outcome in clinical studies. Significant limitations for timely flare ascertainment exist, and…
Abstract Number: 117 • 2017 ACR/ARHP Annual Meeting
Using Goutpro to Make Medical Trainees Gout Pros- a Single Blinded Randomized Control Study
Linh Ngo¹, Eric Miller², Peter A. Valen³ and Alisa Duran⁴, ¹Division of Rheumatology, University of Minnesota, Minneapolis, MN, ²Medicine, Hennepin County Medical Center, Minneapolis, MN, ³Rheumatology/ Dept of Medicine, University of Minnesota/Minneapolis VAMC, Minneapolis, MN, ⁴Department of Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: Gout is the most common type of inflammatory arthritis in the U.S., affecting 4% of the population. Despite modern advancements and the availability of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].